Atlas Trials

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

Clinical trial NCT05922501 · RECRUITING

Trial details

NCT number
NCT05922501
Sponsor
Massachusetts General Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed CancerRefractory Multiple MyelomaMultiple Myeloma
Start date
2024-05-31
Primary completion
2028-12-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.